Latest Headlines

Latest Headlines

India's patent office nixes Takeda diabetes application

The patent office in India has slapped down an application from Tokyo-based Takeda Pharmaceutical for its single-dose Type 2 diabetes treatment dipeptidyl peptidase 4 (DPP-4) inhibitor.

Novartis expects India's Sun to meet February U.S. generic Gleevec launch

Switzerland-based Novartis sees Mumbai-based Sun Pharmaceutical Industries meeting its February target start date for sales of generic Gleevec/Glivec (imatinib), putting the Indian drugmaker in the spotlight on the deadline.

India's Supreme Court allows Cipla move in Roche patent case

The Supreme Court of India will allow a scientist to join the patent case involving Indian drug giant Cipla which had earlier been found to have violated the Roche patent on its Tarceva (erlotinib) cancer drug.

India's drugs for domestic use fall short in quality tests, task force says

Medicines produced in India for domestic consumption are failing quality tests performed by a government task force set up to investigate poor manufacturing practices.

India gets kudos for TB testing regime

A recent study in The Lancet showed that India is outperforming other so-called high-burden countries in offering the cheapest access to the World Health Organization-approved Xpert MTB/RIF screening for TB.

New IP rules in EU could cut Indian pharma shipments

Changes in intellectual property (IP) rules in the European Union have Indian drugmakers worried because the new regulations empower EU countries like Belgium to impound Indian-made drugs that are transshipped via the EU to developing countries in Latin America and Africa, according to a report by the Economic Times.

India and France committed to restart trade talks stalled on GVK row

The governments of India and France have agreed to make up for lost time and said this week they remain committed to restarting free trade negotiations between New Delhi and the European Union that have been stalled for the past three years.

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling.

Indian firms in a race to buy Nasdaq-listed Sagent, report says

A slew of Indian drugmakers are in a race to buy U.S.-based Sagent Pharmaceuticals, the Economic Times reports, suggesting a price tag north of $500 million and competition between large generics companies and private equity.

India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat

Bangalore-based Indian drugmaker Biocon drew some brickbats from analysts after third-quarter earnings were released because of disappointing progress in sales of biopharma products, prompting management to go into details about plans to grow the business.